Reviewed & approved by Dr. Nova Reyes · Last checked 2026-10-25. ← Back to Evidence Library
Bronchogen: what the evidence says
At a glance
What it is: a synthetic tetrapeptide from V. Kh. Khavinson's "peptide bioregulator" program, sold as a bronchial bioregulator. Unknown Most papers give Ala-Glu-Asp-Leu ("AEDL") R3; one 2011 PubMed title gives Ala-Asp-Glu-Leu. R4 UNVERIFIED which sequence products on sale contain.
What the evidence says: no published human study tests the bronchitis or COPD use it is sold for. The only evidence for that use is two rat-model studies from one group R1, R2; DNA lab and modeling work is listed in Study details. R3, R4
Biggest risks: unknown. No human safety data were found. Unknown Gray-market products add quality risks.
Rating
| Human Human evidence | No human data |
| Animal Animal / lab evidence | Reported: rat COPD-model studies from one St. Petersburg pulmonology group R1, R2; DNA-binding lab work R3, R4 |
| Regulatory | Not FDA-approved (no Drugs@FDA entry found) R6 · Russia: registration status UNVERIFIED · WADA: not named on the 2026 List R5; S0 status UNVERIFIED |
| Established human dose | None. Study details lists what studies used where reported |
Evidence verdict: Human: No human data · No published human studies of the marketed use (bronchitis/COPD) Card verdict: No human data · No published human studies of the marketed use (bronchitis/COPD) Card note: No published human study tests the bronchitis/COPD use it is sold for; rat-model work only.
This page reports what studies used. It is not dosing advice.
Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source
About the evidence (developer-led): most of this literature comes from V. Kh. Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and allied Russian, Ukrainian and Georgian groups. Many papers are short, Russian-language, and not independently repeated. Read the findings as the developers' own reports. The rat COPD studies come from the Pavlov First St. Petersburg State Medical University pulmonology institute, without Khavinson listed in the abstract author line. R1, R2
What is it?
Bronchogen is a 4-amino-acid peptide that the developers say acts on bronchial lining cells. R3 The proposed mechanism is direct binding to DNA. R3, R4 That idea is the developers' hypothesis and has not been confirmed independently. Unknown Related page: Chonluten.
Does it work?
- Animal Rat COPD model: rats exposed to nitrogen dioxide for 60 days, then given Bronchogen for 1 month, showed less airway remodeling, more normal lining cells, more secretory IgA and less neutrophil inflammation. R1, R2
- Unknown Chronic bronchitis or COPD in people: no published studies found in PubMed. UNVERIFIED whether Russian-language clinical reports exist outside PubMed.
- Unknown Independent trials: none found.
- DNA test-tube and computer-modeling work is listed in Study details only. R3, R4
Is it safe?
- Unknown No human safety data found.
- Unknown Long-term effects unknown.
Gray-market "research use only" Bronchogen: extra risks
Unknown contents. Vials or capsules sold online as "research use only" are not made under drug-quality rules, so identity, strength and sterility are unknown. This is a general caution; we have not found independent testing data for this product. Unknown Vendor claims about effects in people are marketing, not evidence. Unknown
What we don't know
- Unknown Whether it does anything in people
- Unknown Whether a short peptide like this survives digestion or reaches tissues when swallowed or injected
- Unknown What is actually in a gray-market vial or capsule sold under this name
Is it legal?
US: not FDA-approved; no application found in Drugs@FDA data (Oct 25, 2026). R6 Russia: UNVERIFIED whether registered as a medicine in GRLS or sold only as a dietary supplement. EU, UK, Japan, China: UNVERIFIED not checked against EMA, MHRA, PMDA or NMPA. WADA: not named on the 2026 Prohibited List R5; S0 (non-approved substances) would apply if it holds no current approval anywhere, which is UNVERIFIED.
Study details
These are amounts researchers used, not recommendations.
R1 Animal Animal: rat COPD model (Kuzubova 2015)
| Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation |
|---|---|---|---|---|---|---|---|
| Kuzubova 2015 | Rats with NO2-induced COPD model | Not in abstract | Not in abstract | 1 month of treatment | Less goblet-cell hyperplasia, metaplasia, emphysema; more secretory IgA | Animal; group sizes not in abstract | PMID 26468022 |
R2 Animal Animal: rat COPD model, inflammation (Titova 2017)
| Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation |
|---|---|---|---|---|---|---|---|
| Titova 2017 | Rats with NO2-induced COPD model | Not in abstract | Not in abstract | Not in abstract | Less neutrophilic inflammation; restored epithelium, secretory IgA, surfactant protein B | Animal; Russian-language | PMID 30199201 |
R3 Animal Computer model: DNA docking (Khavinson 2016)
| Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation |
|---|---|---|---|---|---|---|---|
| Khavinson 2016 | Docking models of 19 short peptides with DNA | Not applicable | Not applicable | Not applicable | AEDL predicted to bind "ctcc" DNA sequence | Modeling only; developer-led | PMID 27909961 |
R4 Animal Lab: DNA thermostability (Monaselidze 2011)
| Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation |
|---|---|---|---|---|---|---|---|
| Monaselidze 2011 | Calf thymus and mouse liver DNA | In vitro | Not applicable | Not applicable | DNA melting temperature up 3.1°C | Test tube only; title gives Ala-Asp-Glu-Leu | PMID 21240358 |
Full reference list (PubMed entries checked Oct 25, 2026)
- R1 Kuzubova NA, et al. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med. 2015. PMID 26468022
- R2 Titova ON, et al. [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]. Ross Fiziol Zh Im I M Sechenova. 2017. PMID 30199201
- R3 Khavinson VK, et al. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016. PMID 27909961
-
R4 Monaselidze JR, et al. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011. PMID 21240358
-
R5 WADA. The 2026 Prohibited List (in force 1 January 2026). https://www.wada-ama.org/en/prohibited-list
- R6 FDA. Drugs@FDA data (openFDA drugsfda endpoint), searched "bronchogen" Oct 25, 2026: no application found. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:bronchogen · Drugs@FDA: https://www.accessdata.fda.gov/scripts/cder/daf/
Disclaimer
This page is for education and harm reduction, not medical advice or a recommendation to use Bronchogen. Talk to a clinician you trust before using any drug, and report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).
Approved for Adam Greene by Dr. Nova Reyes, 2026-10-25.